24/7 Market News Snapshot 19 May, 2025 – Novavax Inc (NASDAQ:NVAX)

May 19, 2025

DENVER, Colo., 19 May, 2025 (www.247marketnews.com) – (NASDAQ:NVAX) are discussed in this article.
Novavax, Inc. has announced a remarkable bullish trend, with shares trading at $8.036 in pre-market activity, representing an impressive 19.41% increase from the previous close of $6.730. The trading volume has reached 5.21 million shares, indicating robust investor interest and potential upward momentum. This surge in stock price is likely linked to the recent FDA approval of its Biologics License Application (BLA) for Nuvaxovid™, a vital regulatory milestone that enhances confidence among investors.

The FDA’s approval signifies that Novavax can provide its protein-based COVID-19 vaccine to individuals aged 65 and older, as well as those aged 12 to 64 with underlying health risks. This strategic advancement not only marks a crucial step in public health but also triggers a $175 million milestone payment from its collaborator, Sanofi, under their partnership agreement. Novavax’s President and CEO, John C. Jacobs, highlighted that this approval offers vital vaccination access to vulnerable populations, reinforcing the company’s ongoing efforts to combat the pandemic.

The approval of Nuvaxovid™ is substantiated by data from pivotal Phase 3 clinical trials demonstrating both safety and efficacy in preventing COVID-19. Furthermore, Novavax is set to conduct a post-marketing commitment study targeting individuals aged 50 to 64 without high-risk conditions to further assess the vaccine’s performance.

In anticipation of future developments, Novavax expects to be ready for the commercial rollout of the COVID-19 vaccine this fall, contingent upon FDA recommendations. The vaccine has been operating under Emergency Use Authorization since July 2022 and has gained full approvals in various countries globally. Together, these factors not only fortify Novavax’s position in vaccine innovation but also signal a promising trajectory in the ongoing efforts against COVID-19.

Related news for (NVAX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.